Foglia & Partners advised Alfasigma, with a team coordinated by Matteo Carfagnini and composed of Francesco Capogrossi, Emanuele Gentile and Carolina Castelli, on all tax aspects related to the investment in SOFAR S.p.A., an Italian pharmaceutical company with more than fifty years of operational history in the research, production and marketing of drugs, medical devices and dietary supplements.
Alfasigma, through the signing of the agreement, acquires the entire share capital of SOFAR, enriching its product portfolio especially in the gastroenterological area, where SOFAR holds brands such as Enterolactis, Pentacol and Gerdoff.
Alfasigma is one of Italy’s leading pharmaceutical companies, focusing on prescription specialties, self-medication products and nutraceuticals. Formed in 2015 from the merger of the Alfa Wassermann and Sigma-Tau groups, Alfasigma now has subsidiaries and distributors in about 90 countries worldwide.